In a successful week for the medical technology companies in the LSI Alumni community, we saw multiple LSI Alumni acquisitions, over $50 million raised, FDA 510(k) clearance, and much more on the road to LSI Europe '24 in Sintra, Portugal this September.
Announced the appointment of James A. Heinz as new CEO. The company delivers simple and secure technology for vessel and tubular structure occlusion. In addition to its temporary trauma solution, it is also commercializing a permanent implant (SCureClamp™).
Announced the treatment of their first patient with NeoCast™. NeoCast is built to address the limitations of existing embolic products for indications where deep penetration into the microvasculature is desired.
Announced the first clinical use of its HOTWIRE™ Radiofrequency (RF) Guidewire System at St. Bernards Medical Center. The company's proprietary HOTWIRE™ system, featuring universal sheath compatibility, aims to enhance outcomes and streamline workflows for physicians treating cardiovascular disease in millions of patients worldwide.
Launched telehealth services for women seeking effective first-line incontinence treatment in collaboration with UpScript Health. The company's Leva® Pelvic Health System offers an innovative, non-invasive, medication-free way for women to train and strengthen their pelvic floor muscles—at home in just five minutes a day—to treat urinary incontinence (UI) and chronic fecal incontinence (FI).
Announced the conditional acquisition of Compliance Solutions Life Sciences by Abingdon Health. Together, the two companies will significantly enhance and expand quality, regulatory, and clinical services through the acquisition.
Announced Steve Motes as new Chief Strategy Officer for the US. With over 20 years of experience leading high-performing teams and a strong track record in global marketing and commercialization, Steve brings a wealth of expertise to the company.
Announced the successful completion of a preclinical study for its ForePass® Endoscopic Bypass System. The company is poised for the final preparatory work leading up to our human trials following the development of their device and delivery system.
Closed an oversubscribed Seed round of $1.2M led by NuFund Venture Group. The company's non-invasive diagnostic tool platform and technology capture sound vibrations and positional data to determine cartilage deterioration in joints. Currently, this technology is applied to the knee joint.
Raised a ₩20 billion ($14.5 million) Series B funding round led by LB Investment, a leading venture capital firm in Korea. With this investment, the company intends to enter the domestic and overseas markets for its cardiovascular interventional robot.
Raised a $15M Series A funding round led by Fulcrum Equity Partners with continued support from existing investors, Stage 2, and LiveOak Ventures. MedScout is a revenue acceleration platform designed to transform sales processes for Medtech and life sciences companies.
Obtained clinical trial authorization for the treatment of ACLF in France. The company is developing a novel technology to remove free metals from the blood. Its technology combines dialysis and nanotechnology to restore metal homeostasis in patients with Acute Kidney Injury and Wilson's disease.
Announced the company has been acquired by Stryker. MOLLI specializes in developing a wire-free soft tissue localization technology that helps surgeons mark the precise location of a lesion for removal during breast-conserving surgery.
Announced the appointment of John Mack to its Board of Directors. The company is accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies.
Received FDA 510(k) clearance for its P-Scope Device. The P-Scope is a minimally invasive diagnostic device that transforms abdominal cavity examinations by offering a safer, more efficient, and cost-effective alternative to traditional methods.
Announced the appointment ofLSI Alumni Yvonne Bokelman as Chairman of the Board of Directors. The company has developed a portfolio of early projects in indications with high unmet medical needs, starting with Gout flare, Osteoarthritis, and more.
Received €20 million in venture-debt financing from the European Investment Bank (EIB) to support clinical trials, research and development, and market access programs for the ProtEmbo cerebral embolic protection system. ProtEmbo is inserted during TAVR via the artery in the left wrist, and lines the roof of the aortic arch, shielding the brain from the dislodged debris.
Announced the world’s first-ever use of Apple Vision Pro, by one of the patients implanted with the Synchron brain computer interface. The company is developing an endovascular BCI designed to restore functionality in people with severe paralysis.
Received de novo clearance from the FDA for a surgical kit designed to help reduce long-term phantom limb pains among people who have had an amputation. The company's Adaptive Hydrogel Technology is engineered to support nerve healing and address the poor and unpredictable outcomes in neuroma prevention, adhesion reduction, and nerve repair.
Closed a $5 million Series A financing round led by Botong Medical. The company develops innovative solutions for the treatment of vascular blockages using advanced, minimally invasive technology.
Raised a €25 million financing round, comprised of both equity investment and a venture debt loan from the European Investment Bank (EIB). This financing round aims to propel both the development of the Heron® lead, WISE’s cutting-edge solution for spinal cord stimulation and the commercial development of the WISE Cortical Strip (WCS®), WISE’s unique electrode for neuromonitoring.
Stay tuned for more updates, insights, and achievements of our LSI Alumni in our Weekly Recap, and follow our blog for the latest medical device news and advancements.
Schedule an exploratory call
Request Info© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
